Literature DB >> 1568291

Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

A Haldane1, G J Finlay, J B Gavin, B C Baguley.   

Abstract

The cytotoxicity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC 601,316), a new experimental DNA-intercalating antitumor drug, against a cultured Lewis lung adenocarcinoma cell line was compared with that of the DNA-intercalating antitumor drug amsacrine. In contrast to amsacrine, AC demonstrated self-inhibition of cytotoxicity following short (3-9 h) incubation periods and exponential killing (with a shoulder) after long (24-72 h) periods of incubation. The difference between these drugs was best demonstrated using a constant concentration x time (C x T) exposure (AC, 12 mumol h l-1; amsacrine, 3 mumol h l-1). In contrast to amsacrine, AC was minimally effective over exposure periods of less than or equal to 1 h and maximally effective over intermediate periods (4-6 h). The results suggest the possibility of designing AC administration protocols that maximise the drug's cytotoxicity towards solid tumors, which, because of diffusion barriers, are subjected to longer drug exposures than are well-vascularised tumours.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568291     DOI: 10.1007/bf00684851

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator.

Authors:  D J Adams
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

2.  Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma.

Authors:  B C Baguley; G J Finlay
Journal:  J Natl Cancer Inst       Date:  1988-04-06       Impact factor: 13.506

Review 3.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.

Authors:  G J Finlay; W R Wilson; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1989-12

5.  Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability.

Authors:  D A Keefe; R L Capizzi; S A Rudnick
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

6.  Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.

Authors:  P Kestell; J W Paxton; P C Evans; D Young; J L Jurlina; I G Robertson; B C Baguley
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

7.  The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.

Authors:  B F Cain; G J Atwell
Journal:  Eur J Cancer       Date:  1974-08       Impact factor: 9.162

8.  Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

Authors:  G J Atwell; G W Rewcastle; B C Baguley; W A Denny
Journal:  J Med Chem       Date:  1987-04       Impact factor: 7.446

9.  Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.

Authors:  E Schneider; S J Darkin; P A Lawson; L M Ching; R K Ralph; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1988-11

10.  Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration--time product.

Authors:  S Ozawa; Y Sugiyama; Y Mitsuhashi; T Kobayashi; M Inaba
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more
  6 in total

1.  Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse.

Authors:  J W Paxton; D Young; S M Evans; I G Robertson; P Kestell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.

Authors:  Christian Dittrich; Veronique Dieras; Pierre Kerbrat; Cornelis Punt; Roberto Sorio; Francesco Caponigro; Xavier Paoletti; Christine de Balincourt; Denis Lacombe; Pierre Fumoleau
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

3.  Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.

Authors:  A Haldane; K M Holdaway; G J Finlay; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.

Authors:  G J Finlay; E Marshall; J H Matthews; K D Paull; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide.

Authors:  B C Baguley; L Zhuang; E Marshall
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049.

Authors:  David J A Bridewell; Andrew C G Porter; Graeme J Finlay; Bruce C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  2008-01-03       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.